MA50144A - Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées - Google Patents

Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées

Info

Publication number: MA50144A
Authority: MA; Morocco
Prior art keywords: n3pglu; peptid; beta; amyloid antibodies; associated uses
Prior art date: 2017-04-20

Application number

MA050144A

Other languages

English (en)

Inventor

Ronald Bradley Demattos

Jirong Lu

Ying Tang

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-04-20

Filing date

2018-04-16

Publication date

2020-07-29

2018-04-16 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2020-07-29 Publication of MA50144A publication Critical patent/MA50144A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Zoology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
General Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Hospice & Palliative Care (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Cell Biology (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

MA050144A 2017-04-20 2018-04-16 Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées MA50144A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201762487550P	2017-04-20	2017-04-20

Publications (1)

Publication Number	Publication Date
MA50144A true MA50144A (fr)	2020-07-29

Family

ID=62111232

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA050144A MA50144A (fr)	2017-04-20	2018-04-16	Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées

Country Status (28)

Country	Link
US (3)	US10647759B2 (fr)
EP (1)	EP3612559A1 (fr)
JP (3)	JP6900500B2 (fr)
KR (2)	KR102567295B1 (fr)
CN (2)	CN110582511B (fr)
AR (1)	AR111208A1 (fr)
AU (2)	AU2018255221B2 (fr)
BR (1)	BR112019018810A2 (fr)
CA (1)	CA3058482C (fr)
CL (1)	CL2019002922A1 (fr)
CO (1)	CO2019011349A2 (fr)
CR (1)	CR20190445A (fr)
DO (1)	DOP2019000241A (fr)
EA (1)	EA201992163A1 (fr)
EC (1)	ECSP19075146A (fr)
IL (1)	IL269003B2 (fr)
JO (1)	JOP20190247A1 (fr)
MA (1)	MA50144A (fr)
MX (2)	MX2019012445A (fr)
NZ (1)	NZ758066A (fr)
PE (1)	PE20200011A1 (fr)
PH (1)	PH12019502361A1 (fr)
SA (1)	SA519410311B1 (fr)
SG (1)	SG11201909022PA (fr)
TW (2)	TWI705975B (fr)
UA (1)	UA126806C2 (fr)
WO (1)	WO2018194951A1 (fr)
ZA (2)	ZA201906159B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW201827467A (zh)	2016-11-03	2018-08-01	比利時商健生藥品公司	焦穀胺酸類澱粉蛋白－β之抗體及其用途
TWI705975B (zh) *	2017-04-20	2020-10-01	美商美國禮來大藥廠	抗－N3pGlu類澱粉β肽抗體及其用途
MA55491A (fr)	2019-03-26	2022-02-09	Janssen Pharmaceutica Nv	Anticorps anti-pyroglutamate-amyloïde bêta et leurs utilisations
WO2021151011A2 (fr) *	2020-01-24	2021-07-29	The Board Of Trustees Of Western Michigan University	Traitement de protéinopathies neurodégénératives à l'aide d'une molécule inhibitrice de l'apoptose fas (faim) ou d'un de ses fragments et/ou mimétiques
IL301572A (en) *	2020-10-02	2023-05-01	Lilly Co Eli	Methods for reducing the protein content of the host cell in protein purification processes
TWI843040B (zh)	2021-01-11	2024-05-21	美商美國禮來大藥廠	抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh)	2021-03-12	2023-01-01	美商美國禮來大藥廠	抗類澱粉β抗體及其用途
TW202300518A (zh)	2021-03-12	2023-01-01	美商美國禮來大藥廠	抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (fr)	2021-05-24	2022-12-01	Eli Lilly And Company	Anticorps anti-amyloïde bêta et leurs utilisations
JP7268910B2 (ja) *	2021-09-16	2023-05-08	株式会社ユニバーサルエンターテインメント	遊技機
JP7306745B2 (ja) *	2021-09-16	2023-07-11	株式会社ユニバーサルエンターテインメント	遊技機
JP7306746B2 (ja) *	2021-09-16	2023-07-11	株式会社ユニバーサルエンターテインメント	遊技機
CN118139880A (zh) *	2021-10-22	2024-06-04	伊莱利利公司	O-连接的n-乙酰葡糖胺水解酶(oga)抑制剂联合治疗
TW202334210A (zh)	2021-10-29	2023-09-01	美商美國禮來大藥廠	靶向介白素-34之化合物及方法
AU2022376940A1 (en) *	2021-10-29	2024-05-02	Eli Lilly And Company	Compounds and methods targeting interleukin-34
AU2022376930A1 (en) *	2021-10-29	2024-05-02	Eli Lilly And Company	Compounds and methods targeting interleukin-34
KR20240105403A (ko)	2021-10-29	2024-07-05	일라이 릴리 앤드 캄파니	인터류킨-34를 표적화하는 화합물 및 방법
JP2025506411A (ja)	2022-02-03	2025-03-11	イーライリリーアンドカンパニー	アルツハイマー病の診断及び治療のための局所タウイメージング
CN117327168A (zh) *	2022-06-24	2024-01-02	厦门大学	B2M-GluN1封闭肽、其药物组合物及用途
JP2025540659A (ja) *	2022-11-17	2025-12-16	イーライリリーアンドカンパニー	抗Ｎ３ｐＧｌｕアミロイドベータ抗体、用量、及びその使用
EP4638494A1 (fr)	2022-12-22	2025-10-29	BioArctic AB	Anticorps se liant à abêtape3
WO2025106313A1 (fr)	2023-11-14	2025-05-22	Eli Lilly And Company	Dosages basés sur récepteur fc destinés à l'analyse d'anticorps igg
WO2025228316A1 (fr) *	2024-04-28	2025-11-06	Jacobio Pharmaceuticals Co., Ltd.	Anticorps anti-bêta-amyloïdes n3pglu et leurs utilisations
WO2025255300A1 (fr) *	2024-06-06	2025-12-11	Eli Lilly And Company	Formulations pour anticorps anti-n3pglu amyloïde bêta
TW202607032A (zh)	2024-06-20	2026-02-16	瑞典商生物極公司	雙特異性結合分子
WO2026012421A1 (fr) *	2024-07-11	2026-01-15	齐鲁制药有限公司	ANTICORPS β-AMYLOÏDE ANTI-N3PGLU ET SON UTILISATION
CN118459583B (zh) *	2024-07-11	2024-09-10	齐鲁制药有限公司	抗N3pGlu淀粉样蛋白β抗体及其用途
WO2026075947A1 (fr)	2024-10-01	2026-04-09	Eli Lilly And Company	Régimes posologiques pour la maladie d'alzheimer précoce

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL151378A0 (en) *	2000-02-24	2003-04-10	Univ Washington	Humanized antibodies that sequester amyloid beta peptide
US7122374B1 (en)	2002-04-09	2006-10-17	Takaomi Saido	Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
EP1523499A2 (fr)	2002-07-24	2005-04-20	Innogenetics N.V.	Fragments du peptide beta-amyloide en tant que cibles pour la vaccination contre la maladie d'alzheimer
WO2005025616A1 (fr)	2003-09-09	2005-03-24	Takeda Pharmaceutical Company Limited	Utilisation d'un anticorps
GEP20115195B (en)	2004-07-30	2011-04-11	Rinat Neuroscience Corp	Antibodies directed against amyloid-beta peptide and use thereof
PE20061323A1 (es) *	2005-04-29	2007-02-09	Rinat Neuroscience Corp	Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
NZ574188A (en)	2006-07-14	2012-05-25	Ac Immune Sa	Humanized antibody against amyloid beta
WO2009149487A2 (fr)	2008-06-12	2009-12-17	Affiris Ag	Composés destinés au traitement de symptômes associés à la maladie de parkinson
CA2730073A1 (fr)	2008-07-09	2010-01-14	University Of Zurich	Procede d'activation de la neurogenese
EP3338795A1 (fr)	2008-07-21	2018-06-27	Probiodrug AG	Dosage d'anticorps de diagnostic
US8795664B2 (en)	2010-06-04	2014-08-05	Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin	Monoclonal antibodies targeting amyloid beta oligomers
WO2012021475A2 (fr)	2010-08-12	2012-02-16	Eli Lilly And Company	ANTICORPS CONTRE LE PEPTIDE N3pGLU AMYLOÏDE BÊTA ET LEURS UTILISATIONS
DK3339323T3 (da) *	2010-08-12	2020-01-20	Lilly Co Eli	Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf
WO2015175769A1 (fr) *	2014-05-15	2015-11-19	Biogen Ma Inc.	Procédés de détection d'oligomères bêta-amyloïdes dans des échantillons biologiques
TWI599358B (zh) *	2014-09-16	2017-09-21	美國禮來大藥廠	組合療法
IL310723A (en) *	2015-04-13	2024-04-01	Pfizer	Therapeutic antibodies and their uses
JOP20170004B1 (ar) *	2016-01-15	2022-09-15	Lilly Co Eli	الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI735600B (zh)	2016-07-01	2021-08-11	美商美國禮來大藥廠	抗－N3pGlu類澱粉β肽抗體及其用途
TWI705975B (zh) *	2017-04-20	2020-10-01	美商美國禮來大藥廠	抗－N3pGlu類澱粉β肽抗體及其用途

2018
- 2018-04-09 TW TW107112023A patent/TWI705975B/zh active
- 2018-04-09 TW TW109140166A patent/TWI789644B/zh active
- 2018-04-09 AR ARP180100882A patent/AR111208A1/es unknown
- 2018-04-16 UA UAA201910202A patent/UA126806C2/uk unknown
- 2018-04-16 CN CN201880025982.6A patent/CN110582511B/zh active Active
- 2018-04-16 CR CR20190445A patent/CR20190445A/es unknown
- 2018-04-16 NZ NZ758066A patent/NZ758066A/en unknown
- 2018-04-16 EA EA201992163A patent/EA201992163A1/ru unknown
- 2018-04-16 MX MX2019012445A patent/MX2019012445A/es unknown
- 2018-04-16 JP JP2019551563A patent/JP6900500B2/ja active Active
- 2018-04-16 WO PCT/US2018/027718 patent/WO2018194951A1/fr not_active Ceased
- 2018-04-16 KR KR1020227001314A patent/KR102567295B1/ko active Active
- 2018-04-16 MA MA050144A patent/MA50144A/fr unknown
- 2018-04-16 KR KR1020197030416A patent/KR102352670B1/ko active Active
- 2018-04-16 BR BR112019018810A patent/BR112019018810A2/pt unknown
- 2018-04-16 CA CA3058482A patent/CA3058482C/fr active Active
- 2018-04-16 SG SG11201909022P patent/SG11201909022PA/en unknown
- 2018-04-16 JO JOP/2019/0247A patent/JOP20190247A1/ar unknown
- 2018-04-16 IL IL269003A patent/IL269003B2/en unknown
- 2018-04-16 PE PE2019002050A patent/PE20200011A1/es unknown
- 2018-04-16 CN CN202310757235.4A patent/CN117024583A/zh active Pending
- 2018-04-16 US US15/953,716 patent/US10647759B2/en active Active
- 2018-04-16 EP EP18722325.0A patent/EP3612559A1/fr active Pending
- 2018-04-16 AU AU2018255221A patent/AU2018255221B2/en active Active
2019
- 2019-09-18 ZA ZA2019/06159A patent/ZA201906159B/en unknown
- 2019-09-20 DO DO2019000241A patent/DOP2019000241A/es unknown
- 2019-10-14 CL CL2019002922A patent/CL2019002922A1/es unknown
- 2019-10-15 CO CO2019011349A patent/CO2019011349A2/es unknown
- 2019-10-16 SA SA519410311A patent/SA519410311B1/ar unknown
- 2019-10-17 PH PH12019502361A patent/PH12019502361A1/en unknown
- 2019-10-17 MX MX2022011817A patent/MX2022011817A/es unknown
- 2019-10-18 EC ECSENADI201975146A patent/ECSP19075146A/es unknown
2020
- 2020-04-08 US US16/843,503 patent/US11078261B2/en active Active
- 2020-12-17 ZA ZA2020/07868A patent/ZA202007868B/en unknown
2021
- 2021-06-14 AU AU2021203927A patent/AU2021203927B2/en active Active
- 2021-06-16 JP JP2021099897A patent/JP7227312B2/ja active Active
- 2021-08-02 US US17/391,821 patent/US20210371509A1/en not_active Abandoned
2023
- 2023-02-09 JP JP2023018535A patent/JP7532571B2/ja active Active

Also Published As

Publication number	Publication date
TWI705975B (zh)	2020-10-01
US10647759B2 (en)	2020-05-12
WO2018194951A1 (fr)	2018-10-25
CA3058482C (fr)	2023-05-09
JP2020510081A (ja)	2020-04-02
JP2023058623A (ja)	2023-04-25
CR20190445A (es)	2019-11-06
KR102352670B1 (ko)	2022-01-19
IL269003A (en)	2019-10-31
KR20220011800A (ko)	2022-01-28
JP2021151253A (ja)	2021-09-30
KR20190129100A (ko)	2019-11-19
TWI789644B (zh)	2023-01-11
EP3612559A1 (fr)	2020-02-26
TW202120541A (zh)	2021-06-01
CO2019011349A2 (es)	2019-10-31
IL269003B1 (en)	2025-06-01
US20180305444A1 (en)	2018-10-25
DOP2019000241A (es)	2019-10-15
MX2019012445A (es)	2020-01-13
EA201992163A1 (ru)	2020-03-02
JP6900500B2 (ja)	2021-07-07
US20200262902A1 (en)	2020-08-20
CA3058482A1 (fr)	2018-10-25
KR102567295B1 (ko)	2023-08-16
NZ758066A (en)	2022-10-28
AU2021203927A1 (en)	2021-07-08
AU2021203927B2 (en)	2024-03-21
AU2018255221B2 (en)	2021-07-01
UA126806C2 (uk)	2023-02-08
CL2019002922A1 (es)	2020-03-13
US20210371509A1 (en)	2021-12-02
PE20200011A1 (es)	2020-01-06
SG11201909022PA (en)	2019-11-28
CN110582511B (zh)	2023-08-08
TW201902924A (zh)	2019-01-16
ZA202007868B (en)	2023-06-28
US11078261B2 (en)	2021-08-03
IL269003B2 (en)	2025-10-01
AU2018255221A1 (en)	2019-09-19
MX2022011817A (es)	2022-10-10
BR112019018810A2 (pt)	2020-05-05
CN110582511A (zh)	2019-12-17
ZA201906159B (en)	2026-03-25
AR111208A1 (es)	2019-06-12
SA519410311B1 (ar)	2022-03-20
JOP20190247A1 (ar)	2019-10-20
PH12019502361A1 (en)	2020-07-13
JP7227312B2 (ja)	2023-02-21
JP7532571B2 (ja)	2024-08-13
ECSP19075146A (es)	2019-10-31
CN117024583A (zh)	2023-11-10

Publication	Publication Date	Title
EP3762030A4 (fr)	2022-01-05	Anticorps anti-cd73 et utilisations associées
EP3625263A4 (fr)	2021-05-05	Anticorps anti-galectine-9 et leurs utilisations
EP3383916A4 (fr)	2019-09-11	Anticorps anti-cd73 et leurs utilisations
EP3389702A4 (fr)	2019-08-14	Anticorps anti-lag-3 et leurs utilisations
EP3838289A4 (fr)	2022-08-03	Anticorps anti-tigit et ses utilisations
EP3626825A4 (fr)	2021-02-17	Anticorps anti-cdh6 et conjugué anticorps anti-cdh6-médicament
MA47789A (fr)	2020-01-22	Anticorps anti-phf-tau et leurs utilisations
EP3504243A4 (fr)	2020-03-11	Anticorps anti-tim-3 et leurs utilisations
EP3759143A4 (fr)	2022-03-02	Anticorps anti-tigit et leurs utilisations
EP3658589C0 (fr)	2023-09-27	Anticorps anti-sirp-alpha et méthodes associées
EP3426288A4 (fr)	2019-10-30	Anticorps anti-pacap et leurs utilisations
MA49683A (fr)	2020-06-03	Anticorps anti-cd8 et leurs utilisations
EP3733702A4 (fr)	2021-09-29	Anticorps anti-lag-3 et utilisations associées
EP3735427A4 (fr)	2021-09-15	Anticorps anti-mct1 et utilisations associées
EP3684812A4 (fr)	2021-09-08	Anticorps anti-ctla4 et utilisations associées
MA46704A (fr)	2019-09-11	Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
MA46708A (fr)	2021-05-05	Anticorps anti-pd1 et leurs utilisations
MA49886A (fr)	2020-06-24	Anticorps anti-par2 et leurs utilisations
MA49537A (fr)	2020-05-13	Anticorps anti-lag3 et leurs utilisations
EP3484499A4 (fr)	2020-05-13	Anticorps anti-tgfb, méthodes et utilisations
MA45125A (fr)	2021-06-02	Anticorps anti-alpha-synucléine et leurs utilisations
EP3283517A4 (fr)	2019-03-06	Anticorps anti-pacap et leurs utilisations
EP3645563A4 (fr)	2021-03-17	Anticorps anti-fam19a5 et leurs utilisations
EP3883967A4 (fr)	2023-04-19	Anticorps anti-cd38 et anti-icam1 et utilisations correspondantes
MA45543A (fr)	2019-05-08	Anticorps anti-peptides n3pglu amyloïdes bêta et utilisations associées